Construction of a nomogram model based on biomarkers for liver metastasis in non‐small cell lung cancer
Authors:
Open Access
- 4 August 2024
- journal article
- research article
- Published by Wiley in Thoracic Cancer
- Vol. 15 (26) , 1897-1911
Abstract
Background: Patients with non‐small cell lung cancer (NSCLC) with liver metastasis have a poor prognosis, and there are no reliable biomarkers for predicting disease progression. Currently, no recognized and reliable prediction model exists to anticipate liver metastasis in NSCLC, nor have the risk factors influencing its onset time been thoroughly explored.Methods: This study conducted a retrospective analysis of 434 NSCLC patients from two hospitals to assess the association between the risk and timing of liver metastasis, as well as several variables.Results: The patients were divided into two groups: those without liver metastasis and those with liver metastasis. We constructed a nomogram model for predicting liver metastasis in NSCLC, incorporating elements such as T stage, N stage, M stage, lack of past radical lung cancer surgery, and programmed death ligand 1 (PD‐L1) levels. Furthermore, NSCLC patients with wild‐type EGFR, no prior therapy with tyrosine kinase inhibitors (TKIs), and no prior radical lung cancer surgery showed an elevated risk of early liver metastasis.Conclusion: In conclusion, the nomogram model developed in this study has the potential to become a simple, intuitive, and customizable clinical tool for assessing the risk of liver metastasis in NSCLC patients following validation. Furthermore, it provides a framework for investigating the timing of metachronous liver metastasis.Keywords
Funding Information
- Key Science and Technology Program of Shaanxi Province (2022JQ‐784)
- Natural Science Basic Research Program of Shaanxi Province (2022JQ‐796)
This publication has 51 references indexed in Scilit:
- First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 TrialJournal of Thoracic Oncology, 2022
- Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinomaEuropean Radiology, 2020
- Endothelial and Inflammation Biomarker Profiles at Diagnosis Reflecting Clinical Heterogeneity and Serving as a Prognostic Tool for Treatment Response in Two Independent Cohorts of Patients With Juvenile DermatomyositisArthritis & Rheumatology, 2020
- The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastasesJournal of Cancer Research and Clinical Oncology, 2019
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trialThe Lancet, 2019
- Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancerLung Cancer, 2018
- Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with NivolumabJournal of Thoracic Oncology, 2017
- PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lungHuman Pathology, 2016
- Carotid sparing intensity-modulated radiation therapy achieves comparable locoregional control to conventional radiotherapy in T1-2N0 laryngeal carcinomaOral Oncology, 2015
- Metastatic sites and survival in lung cancerLung Cancer, 2014